Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine

Chahinian, P

doi:10.1001/jama.237.22.2392

Cited by 12 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The characteristics of the patients are summarized in table 1, where they are compared to patients of three previous series [3,4,10], On average, 4 courses of chemotherapy (range 1-13) were administered. The evaluation of tumor response was possible in 76 patients.…”

Section: Resultsmentioning

confidence: 99%

“…At the end of the staging procedures, each patient was classified ac cording to the TNM system of the International Union Against Cancer (U1CC) [7], The MACC regimen was given in the dose and schedule origi nally designed by Chahinian et at. [4]: methotrexate 40 mg/m2 i.v. ; adriamycin 40 mg/m2 i.v.…”

Section: Methodsmentioning

confidence: 99%

“…On the other hand, the real antitumor activity of the MACC program has been called into question by the results of a multicenter study [3], which had been designed to confirm some previous claims of efficacy [4,5], The current communication summarizes our ex perience with the above mentioned regimen.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination Chemotherapy with Methotrexate, Adriamycin, Cyclophosphamide and CCNU (MACC) for Nonsmall Cell Lung Cancer

Buccheri¹,

Ferrigno²,

Vola³

et al. 1989

Oncology

View full text Add to dashboard Cite

Ninety-two nonsmall cell lung cancer (NSCLC) patients were treated with a combination chemotherapy containing methotrexate, adriamycin, cyclophosphamide and CCNU (MACC). The regimen was administered in the dose and schedule originally reported. Median survival for all patients was 32 weeks. Only 6 patients demonstrated an objective response with a median survival rate of 51 weeks. The remaining 70 evaluable patients were nonresponders. These latter patients had a survival probability reduced to 29 weeks. Median time to progression for the whole group was 17 weeks. Partial responses were seen in 3 squamous, 1 large cell carcinoma and 1 adenocarcinoma. One patient with bronchiolo-alveolar carcinoma had complete disease regression and is still alive 136 weeks after starting treatment. Toxicity was significant with 2 treatment-related deaths. The major toxic effects consisted of myelosuppression, nausea, vomiting, and stomatitis. Alopecia was nearly universal; a mild cardiac, renal, or hepatic toxicity was relatively unfrequent. Polychemo-therapy with MACC regimen may benefit a few selected patients with NSCLC, but its overall antitumor efficacy appears to be very limited.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Combination Chemotherapy with Methotrexate, Adriamycin, Cyclophosphamide and CCNU (MACC) for Nonsmall Cell Lung Cancer

Buccheri¹,

Ferrigno²,

Vola³

et al. 1989

Oncology

View full text Add to dashboard Cite

show abstract

“…Das kleinzellige Bronchuskarzinom nimmt unter den verschie denen histologischen Typen dieer Erkrankung insofern eine Sonderstellung ein, als es einerseits äußerst frühzeitig metasta siert, so daß der chirurgischen Therapie kaum ein kurativer Effekt beizumessen ist, andererseits zeigt es im Gegensatz zu den übrigen Bronchuskarzinomen eine hohe Sensibilität sowohl gegenüber ionisierenden Strahlen als auch gegenüber zytostatischen Substanzen [1,2,4,8,10,14,15]. Obwohl in Frühstadien des Bronchuskarzinoms die Chirurgie als kurative Methode unbestritten ist, wird heute deshalb diskutiert, ob bei kleinzelligen Bronchuskarzinomen nicht der Strahlen-und/ oder Chemotherapie der Vorzug zu geben ist.…”

Section: Introductionunclassified

“…Die besten Ergebnisse wurden mit Polychemotherapien, die Adriamycin enthielten, in Kombination mit Strahlentherapie erreicht. So berichtete Gatzemeier et al [6,7] [2] in 85,7% der Fälle eine Remission erreichen, auch die Überle benszeit mit 8,6 Monaten war wesentlich höher als die im Krankengut der oben erwähnten Autoren. Mit Adriamycin, Cyclophosphamid.…”

Section: Introductionunclassified

Kombinierte Chemo- und Radiotherapie bei kleinzelligen Bronchuskarzinomen

Hammer¹,

Krätzer²,

Denz³

et al. 1981

Oncol Res Treat

View full text Add to dashboard Cite

25 Patienten mit kleinzelligem Bronchuskarzinom wurden in einem Zeitraum von 3 Jahren mit einer Kombination von Polychemo- und Radiotherapie behandelt. Als Polychemotherapie wurde Adriamycin, Cyclophosphamid und Vincristin (ACO) gegeben. Nach den ersten 3 Polychemotherapiestößen wurde der Tumor, der homolaterale Hilus und das Mediastinum bestrahlt, anschließend noch 2–3 Polychemotherapiestöße durchgeführt. Bei alien 25 Patienten konnte eine Remission erzielt werden. Die mittlere Remissionsdauer betrug bei lokoregional begrenzter Tumorausbreitung 12 Monate, bei Patienten mit disseminiertem Tumorbefall 8,6 Monate. Die mittlere Überlebenszeit betrug 14 Monate bzw. 10,9 Monate. Die Ergebnisse werden mit denen anderer Arbeitsgruppen verglichen und diskutiert.

show abstract

Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

Buccheri¹,

Ferrigno²,

Curcio³

et al. 1989

Cancer

View full text Add to dashboard Cite

Recommendations concerning the continuation of chemotherapy in nonresponding patients with non-small cell lung cancer (NSCLC) and stable disease after the first chemotherapy test are empirical and often conflicting. Between 1984 and 1987, 116 inoperable NSCLC patients were treated with methotrexate, doxorubicin, cyclophosphamide, and lomustine (MACC regimen). After two or three cycles of therapy, 74 patients were judged to have stable disease and assigned at random either to chemotherapy maintenance with the same regimen (38 subjects) or to chemotherapy discontinuation (36 subjects). The two study groups were comparable for all the major prognostic factors. Median time to progression was 26 weeks for the chemotherapy group compared to 24 weeks for the nonchemotherapy group (P = NS). Median survival was prolonged in the treatment arm (47 weeks) compared to nontreatment arm (30 weeks), which was statistically nonsignificant. A patient self-assessment of the quality of life revealed a significantly worse tolerance to therapy and a better physical condition in the chemotherapy group. Objective MACC toxicity was significant with two treatment-related deaths. This study failed to demonstrate sufficient therapeutic benefits to justify the increased cost and toxicity of continuing treatment in nonresponding NSCLC patients.

show abstract

Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine

Cited by 12 publications

References 0 publications

Combination Chemotherapy with Methotrexate, Adriamycin, Cyclophosphamide and CCNU (MACC) for Nonsmall Cell Lung Cancer

Combination Chemotherapy with Methotrexate, Adriamycin, Cyclophosphamide and CCNU (MACC) for Nonsmall Cell Lung Cancer

Kombinierte Chemo- und Radiotherapie bei kleinzelligen Bronchuskarzinomen

Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

Contact Info

Product

Resources

About